A Non-randomized, Open-label Study to Characterize the Pharmacokinetics of Glivec/Gleevec (Imatinib Mesylate) in Pediatric (Age Range 1 to Less Than 4 Years) Patients With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Trial Profile

A Non-randomized, Open-label Study to Characterize the Pharmacokinetics of Glivec/Gleevec (Imatinib Mesylate) in Pediatric (Age Range 1 to Less Than 4 Years) Patients With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2015

At a glance

  • Drugs Imatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 09 Mar 2012 Actual initiation date changed from Sep 2010 to Oct 2010 as reported by ClinicalTrials.gov.
    • 06 Jul 2011 Additional locations identified as reported by ClinicalTrials.gov.
    • 05 Jul 2011 Actual initiation date (Sep 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top